High Volume Gainers at AMEX Healthcare Sector

Hemispherx BioPharma, Inc (AMEX:HEB)

About Hemispherx BioPharma, Inc Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection. The commercial focus for Ampligen includes application as a treatment for chronic fatigue syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is the United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts.

Statistics Symbol

HEB

Beta:

1.14

Current Price

$0.51

Market Capitalization:

68.97M

52 week range

$0.44 - $0.87

Shares Outstanding

135.24M

Avg Volume

412,046.00

Float:

131.40M

Financials As per its last financial statements ending September 30th, 2010 Hemispherx BioPharma, Inc (AMEX:HEB) generated the total revenue of $0.04 million for the quarter as compared to the revenue of $0.03 million for the same period last year. However the company ended in the net loss of $3.25 million resulting in loss of $0.02 per share for the respective quarter.

The company’s total assets accumulate up to $55.88 million with highest proportion of current assets standing at $38.56 million as on September 30th, 2010. The company maintains high short term liquidity with current ratio of 16.33 times depicting that current assets cover the current liabilities by 16.33 times.

Uluru Inc. (AMEX:ULU)

About Uluru Inc. ULURU Inc. (ULURU) is a diversified specialty pharmaceutical company. The Company is focused in the developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc drug delivery technologies. ULURU’sNanoflex technology system has at its core a system of hydrogel-like nanoparticles composed of a polymer used in manufacturing contact lenses and other the United States Food and Drug Administration (FDA)-approved implants. Utilizing its Nanoflex technology, it has developed three separate development platforms from the system: Nanoflex Powder, Nanoflex Gel and Nanoflex Injectable Liquid. Its Nanoflex Powder is composed of hydrogel particle flakes that aggregate immediately and irreversibly upon contact with physiological fluid, such as wound exudate, forming a nonresorbable film. Its Nanoflex technology is composed of hydrated nanoparticles that are concentrated into a viscoelastic gel.

Statistics Symbol

ULU

Beta:

1.44

Current Price

$0.09

Market Capitalization:

7.80M

52 week range

$0.08 - $0.30

Shares Outstanding

82.12M

Avg Volume

530,835.00

Float:

63.12M

Financials As per its last quarterly financial statements Uluru Inc. (AMEX:ULU) generated the total revenue of $0.06 million for the period ending September 30th , 2010. The company reported the net loss of $1.21 million resulting in loss of $0.01 per share for the respective quarter.

The company’s total assets accumulate up to $10.21 million with highest proportion of fixed assets as intangibles happen to have the value of $5.60 million as on September 30th, 2010. The company maintains strong short term liquidity position with current ratio of 2.52 times depicting that current assets are 2.52 times more than current liabilities.

CEL- SCI Corporation (AMEX:CVM)

About CEL- SCI Corporation CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; new cold fill manufacturing service to the pharmaceutical industry, and LEAPS technology, with two products: H1N1, a swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted. It is the cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer.

Statistics Symbol

CVM

EPS:

0.02

Current Price

$0.89

Market Capitalization:

184.40M

52 week range

$0.43 - $1.12

Beta

2.27

Avg Volume

1.12M

P/E (ttm)

36.14

Financials As the company is in its development stage CEL-SCI Corporation (AMEX:CVM) has not generated any revenues yet. The company reported the net loss of $7.33million resulting in loss of $0.04per share.

The company’s total assets accumulate up to $37.80 million out of which current assets have the highest proportion standing at $29.098 million. The company maintains strong short term liquidity position as its current assets cover the current liabilities by 8.81 times. Moreover the company seemsto be in an ideal debt to equity ratio with total liabilities of $9.95 million as compared to total equity of $27.85million.

Disclaimer: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATER IALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.

We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who choosesto invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.

Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.

This website is a service of Seo Freisin, Inc., a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933.

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.

Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.

Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.

Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.

We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).